The effect of VCE-004 derivatives on Scleroderma and Obesity are presented in the 26th Annual International Cannabinoid Research Society Symposium on the Cannabinoids

01/07/2016

Córdoba, July 1st of 2016. The researchers of the Maimonides Biomedical Research Institute at Córdoba (IMIBIC, Spain), presented the last results obtained in the investigation of VCE-004 derivatives for the treatment of Scleroderma and Obesity at the 26th Annual International Cannabinoid Research Society Symposium on the Cannabinoids (ICRS) hold at Bukovina (Poland). The work performed in collaboration with Vivacell, shows the potential of VCE-004.8 to ameliorate inflammation associated to obesity by targeting both PPARγ and CB2 receptors, as well as the effect of VCE-004.3 on Scleroderma models.

Developed with DoPlanning